31 May 2019 in Cancer Science
The tumor microenvironment offers favorable conditions for tumor progression, and activated fibroblasts, known as cancer‐associated fibroblasts, play a pivotal role. TP53‐deficient cancer cells are known to induce strong fibroblast activation. We aimed to elucidate the oncogenic role of exosomes derived from TP53‐deficient colon cancer cells in fibroblast proliferation and tumor growth. Cancer cell‐derived exosomes (CDEs) were isolated from the conditioned media of cancer cells using a sequential ultracentrifugation method. The effects of exosomes on tumor growth were evaluated using human cell lines (TP53‐WT colon cancer, HCT116; TP53‐mutant colon cancer, HT29; and fibroblasts, CCD‐18Co and WI‐38) and an immune‐deficient nude mouse xenograft model. HCT116 (HCT116sh p53) cells deficient in TP53 accelerated cocultured fibroblast proliferation compared to TP53‐WT HCT116 (HCT116sh control) cells in vitro. Exosomes from HCT116sh p53 cells suppressed TP53 expression of fibroblasts and promoted their proliferation. Xenografts of HCT116sh p53 cells grew significantly faster than those of HCT116sh control cells in the presence of co‐injected fibroblasts, but this difference was diminished by CDE inhibition. Microarray analysis identified upregulation of several microRNAs (miR‐1249‐5p, miR‐6737‐5p, and miR‐6819‐5p) in TP53‐deficient CDEs, which were functionally proven to suppress TP53 expression in fibroblasts. Exosomes derived from TP53‐mutant HT29 cells also suppressed TP53 expression in fibroblasts and accelerated their growth. The proliferative effect of HT29 on cocultured fibroblasts was diminished by inhibition of these miRNAs in fibroblasts. Our results suggest that CDEs play a pivotal role in tumor progression by fibroblast modification. Cancer cell‐derived exosomes might, therefore, represent a novel therapeutic target in colon cancer.
15 September 1994 in Physical Review B
We report the high-resolution temperature-dependent photoemission spectra of FeSi. We measure an extremely small gap of less than 5 meV in contrast to electrical-resistivity, magnetic-susceptibility, and optical-conductivity measurements, which show an activation energy of about 60 meV. The difference in the gap value is attributed to localized states near the Fermi level, which effectively increase the activation energy associated with a charge or spin excitation as observed in conductivity and susceptibility studies. The density of states at the Fermi level increase systematically on increasing temperature and result in a transition to a metallic phase at 300 K. The data suggest that localization effects play an important role in the ground-state properties of FeSi.
2 July 2025 in Gastrointestinal Endoscopy
19 August 2019 in JGH Open
Background and Aim: To investigate whether assessment by magnifying narrow‐band imaging (M‐NBI) based on the classification of the Japan Esophageal Society provides additional value to the estimation of the invasion depth of superficial esophageal squamous cell carcinoma (SCC) compared with assessment by white light endoscopy (WLE) alone.Methods: Endoscopic images of 211 consecutive superficial esophageal SCCs resected by endoscopic submucosal dissection were separated into WLE and M‐NBI images. Depth estimation was performed independently by five evaluators using the numerical depth estimation scale (0 = epithelium (EP)/lamina propria (LPM), 1 = EP/LPM > muscularis mucosa (MM)/shallow submucosa (SM1), 2 = MM/SM1 > EP/LPM, 3 = MM/SM1, 4 = MM/SM1 > deep submucosa (SM2), 5 = SM2 > MM/SM1, 6 = SM2), using primarily WLE images (step 1), and subsequently both WLE and M‐NBI images (step 2). The discordance scores, determined by the average of the five evaluators' difference between the estimated score (from 0 to 6) and pathological score (0 for histologically proven EP/LPM, 3 for MM/SM1, and 6 for SM2), were analyzed in steps 1 and 2.Results: The discordance scores significantly decreased in step 2 (0.53 ± 0.06) compared with those in step 1 (0.79 ± 0.07) (P < 0.001). When the discordance score < 1.5 was regarded as a clinically correct diagnosis, the rate of the clinically correct diagnosis significantly increased in step 2 compared with that in step 1 (81% to 91%, P < 0.001).Conclusion: M‐NBI has an additive value for estimating the invasion depth of superficial esophageal SCCs.
8 September 2025 in DEN Open
Background: Endoscopic full‐thickness resection (EFTR) is an effective treatment method for gastric submucosal tumors (SMTs). We aimed to perform a technical analysis of EFTR in gastric SMT and compare it with the outcome parameters. Method: Sixty‐one gastric SMTs from 60 patients were resected using EFTR. The indication criteria: size, 11–30 mm, connection to the muscularis propria on endoscopic ultrasonography, intraluminal growth type, no ulceration, and histologically evident or clinically suspicious gastrointestinal stromal tumors (GISTs). The following technical improvements were introduced during the study Periods 1–3: routine use of clip‐line traction (Periods 1–3); use of a plastic bag retriever (Periods 2–3); adaptation of the reopenable clip over‐the‐line method (ROLM, Period 3); implementation of no‐touch EFTR (Period 3); and elimination of submucosal injection (Period 3). Results: The endoscopic complete resection rate was 100%, with a similar tumor resection time (median, 50 min) throughout the periods. Specimen damage was less frequent after using the plastic bag retriever in Periods 2 and 3 ( p = 0.001). In Period 3, ROLM required longer full‐thickness defect closure time (39 min, p = 0.011), but it provided secure closure and shortened the fasting days ( p = 0.010). Histological diagnoses included 38 GISTs, 14 leiomyomas, and nine other pathologies. In Period 3, the implementation of no‐touch EFTR increased the resected specimen size (33 mm, p = 0.010) and improved the histological complete (R0) resection rate of the GISTs (13/13, 100%, p = 0.017). Conclusion: Several technical improvements significantly improved the outcomes of EFTR for gastric SMTs, warranting the external validation of this technique.
16 April 2025 in Cancer Science
Cancer‐associated fibroblasts (CAFs), a major component of the tumor microenvironment, play an important role in tumor progression. Colon cancer cells deficient in p53 activate fibroblasts and enhance fibroblast‐mediated tumor growth. Meflin is a CAF marker capable of inhibiting tumor growth. In this study, we investigated the role of Meflin in fibroblasts using human cell lines (colon cancer HCT116 and fibroblasts CCD‐18Co) and clinical specimens. TP53‐suppressed HCT116 (HCT116sh p53) cells cocultured with CCD‐18Co cells showed significantly faster proliferation than HCT116sh control cells. In xenograft experiments, the volume of tumors induced by coinoculation with HCT116sh p53 and CCD‐18Co cells was significantly larger than that induced by HCT116sh control cells co‐inoculated with CCD‐18Co cells. HCT116sh p53 cells increased the levels of CAF‐like phenotypic markers in CCD‐18Co cells. Moreover, Meflin expression was significantly reduced in CCD‐18Co cells cocultured with HCT116sh p53 cells compared to that in CCD‐18Co cells cocultured with HCT116sh control cells. si‐RNA‐mediated inhibition of Meflin activated CCD‐18Co cells into tumor‐promoting CAF‐like cells, which significantly promoted xenograft tumor growth. Overexpression of Meflin in CCD‐18Co cells using lentivirus suppressed fibroblast‐mediated growth of HCT116sh p53 tumor xenografts. The expression of Meflin in CCD‐18Co cells was suppressed by TGF‐β and enhanced by vitamin D. These results indicate that colon cancer cells deficient in p53 suppress Meflin expression in fibroblasts, which affects tumor growth by altering the properties of tumor growth‐promoting CAFs. Our results suggest that targeting Meflin in fibroblasts may be a novel therapeutic strategy for colorectal cancer.